DOP2013000275A - Formulaciones peptídicas de liberación controlada - Google Patents

Formulaciones peptídicas de liberación controlada

Info

Publication number
DOP2013000275A
DOP2013000275A DO2013000275A DO2013000275A DOP2013000275A DO P2013000275 A DOP2013000275 A DO P2013000275A DO 2013000275 A DO2013000275 A DO 2013000275A DO 2013000275 A DO2013000275 A DO 2013000275A DO P2013000275 A DOP2013000275 A DO P2013000275A
Authority
DO
Dominican Republic
Prior art keywords
weight
relates
compositions
controlled release
administration
Prior art date
Application number
DO2013000275A
Other languages
English (en)
Spanish (es)
Inventor
Fredrik Tiberg
Catalin Nistor
Markus Johnsson
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46456496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2013000275(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Camurus Ab filed Critical Camurus Ab
Publication of DOP2013000275A publication Critical patent/DOP2013000275A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
DO2013000275A 2011-05-25 2013-11-22 Formulaciones peptídicas de liberación controlada DOP2013000275A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161489886P 2011-05-25 2011-05-25

Publications (1)

Publication Number Publication Date
DOP2013000275A true DOP2013000275A (es) 2014-05-15

Family

ID=46456496

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2013000275A DOP2013000275A (es) 2011-05-25 2013-11-22 Formulaciones peptídicas de liberación controlada

Country Status (37)

Country Link
US (3) US11433120B2 (enExample)
EP (2) EP2714004B1 (enExample)
JP (2) JP6265888B2 (enExample)
KR (1) KR102066755B1 (enExample)
CN (2) CN103702662B (enExample)
AR (1) AR086577A1 (enExample)
AU (2) AU2012260821B2 (enExample)
BR (1) BR112013030104A8 (enExample)
CA (1) CA2836847C (enExample)
CL (1) CL2013003365A1 (enExample)
CO (1) CO6900117A2 (enExample)
CR (1) CR20130653A (enExample)
CU (1) CU20130158A7 (enExample)
DK (1) DK2714004T3 (enExample)
DO (1) DOP2013000275A (enExample)
EA (1) EA036213B1 (enExample)
EC (1) ECSP13013107A (enExample)
ES (1) ES2984717T3 (enExample)
FI (1) FI2714004T3 (enExample)
GT (1) GT201300292A (enExample)
HR (1) HRP20240781T1 (enExample)
HU (1) HUE067389T2 (enExample)
IL (1) IL229376B (enExample)
LT (1) LT2714004T (enExample)
MX (1) MX361716B (enExample)
MY (1) MY177820A (enExample)
NI (1) NI201300127A (enExample)
PE (1) PE20141484A1 (enExample)
PH (1) PH12013502550B1 (enExample)
PL (1) PL2714004T3 (enExample)
PT (1) PT2714004T (enExample)
RS (1) RS65702B1 (enExample)
SG (1) SG194865A1 (enExample)
SI (1) SI2714004T1 (enExample)
TW (1) TWI624271B (enExample)
WO (1) WO2012160213A1 (enExample)
ZA (1) ZA201309653B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06014095A (es) * 2004-06-04 2007-08-07 Camurus Ab Formulaciones de deposito de lipidos.
WO2013151771A1 (en) 2012-04-05 2013-10-10 Massachusetts Institute Of Technology Immunostimulatory compositions and methods of use thereof
IN2014DN09831A (enExample) * 2012-05-25 2015-08-07 Camurus Ab
PL2877155T3 (pl) 2012-07-26 2021-05-17 Camurus Ab Formulacje opioidowe
EA034855B1 (ru) 2012-07-26 2020-03-30 Камурус Аб Предшественник депо-препарата, содержащий бупренорфин, и способ лечения путем его введения
US10300145B2 (en) 2016-07-15 2019-05-28 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
IL265270B (en) 2016-09-15 2022-09-01 Camurus Ab Prostacyclin analog formulations
IL295457A (en) 2016-09-27 2022-10-01 Camurus Ab Mixtures and formulations containing alkyl ammonium salt edta
BR112019011053A2 (pt) 2016-12-07 2019-10-15 Ra Pharmaceuticals Inc moduladores da atividade do complemento
SG11202004373RA (en) * 2017-11-15 2020-06-29 Rhythm Pharmaceuticals Inc Sustained release peptide formulations
UA128863C2 (uk) 2018-03-02 2024-11-13 Елісіо Терапьютикс, Інк. СПОЛУКА, ЯКА МІСТИТЬ CpG-ОЛІГОДЕЗОКСИНУКЛЕОТИД
CN109091451B (zh) * 2018-09-10 2021-08-13 武汉百纳礼康生物制药有限公司 亲水性药物的油相液晶凝胶前体制剂及其制备方法
WO2020191305A2 (en) 2019-03-20 2020-09-24 Massachusetts Institute Of Technology Uses of amphiphiles in immune cell therapy and compositions therefor
MX2021014450A (es) * 2019-05-29 2022-01-06 Camurus Ab Composiciones de liberacion controlada de lipidos.
CN113368041B (zh) * 2020-07-17 2023-01-03 丽珠医药集团股份有限公司 药物组合物、缓释制剂及其制备方法
MX2023013060A (es) * 2021-05-04 2023-11-15 Camurus Ab Composiciones y metodos para el tratamiento de tumores neuroendocrinos.
WO2024263085A1 (en) * 2023-06-20 2024-12-26 Camurus Ab Compositions and methods for treating acromegaly
WO2025229402A1 (en) 2024-05-02 2025-11-06 Camurus Ab Lipid compositions and methods of use thereof
WO2025229403A1 (en) 2024-05-02 2025-11-06 Camurus Ab Lipid compositions and methods of use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1682091T3 (en) * 2003-11-07 2017-05-15 Camurus Ab COMPOSITIONS OF LIPIDS AND CATIONIC PEPTIDES
MXPA06014095A (es) 2004-06-04 2007-08-07 Camurus Ab Formulaciones de deposito de lipidos.
GB0412530D0 (en) * 2004-06-04 2004-07-07 Camurus Ab Formulation
PL1778187T3 (pl) 2004-08-04 2012-09-28 Camurus Ab Kompozycje tworzące nielamelarne dyspersje
GB0417388D0 (en) * 2004-08-04 2004-09-08 Camurus Ab Composition
JP5171262B2 (ja) * 2005-01-14 2013-03-27 カムルス エービー ソマトスタチン類似体製剤
ATE462409T1 (de) * 2005-01-14 2010-04-15 Camurus Ab Topische bioadhäsive formulierungen
CA2595385C (en) * 2005-01-21 2011-01-25 Camurus Ab Pharmaceutical lipid compositions
AU2006235183B2 (en) * 2005-04-08 2011-02-10 Amylin Pharmaceuticals, Llc Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent
CA2609810C (en) * 2005-06-06 2012-05-22 Camurus Ab Glp-1 analogue formulations
GB0711656D0 (en) * 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) * 2007-08-22 2007-10-03 Camurus Ab Formulations
GB0815435D0 (en) * 2008-08-22 2008-10-01 Camurus Ab Formulations
US8931272B2 (en) * 2010-10-29 2015-01-13 Ford Global Technologies, Llc Method and system for limiting output of a boosted engine
CN104093399B (zh) * 2011-12-05 2018-03-13 卡穆鲁斯公司 鲁棒性控释肽制剂
IN2014DN09831A (enExample) * 2012-05-25 2015-08-07 Camurus Ab
US20230285502A1 (en) * 2016-09-07 2023-09-14 Camurus Ab Mixtures and formulations
IL295457A (en) * 2016-09-27 2022-10-01 Camurus Ab Mixtures and formulations containing alkyl ammonium salt edta

Also Published As

Publication number Publication date
DK2714004T3 (da) 2024-06-10
SG194865A1 (en) 2013-12-30
HUE067389T2 (hu) 2024-10-28
CU20130158A7 (es) 2014-04-24
IL229376A0 (en) 2014-01-30
GT201300292A (es) 2014-08-05
EP4427814A3 (en) 2024-11-20
US20140162944A1 (en) 2014-06-12
US20250121035A1 (en) 2025-04-17
CN103702662A (zh) 2014-04-02
EA036213B1 (ru) 2020-10-14
FI2714004T3 (fi) 2024-07-15
PL2714004T3 (pl) 2024-08-19
SI2714004T1 (sl) 2024-07-31
PE20141484A1 (es) 2014-10-31
MX2013013401A (es) 2013-12-12
MY177820A (en) 2020-09-23
ZA201309653B (en) 2016-05-25
JP2018076327A (ja) 2018-05-17
CO6900117A2 (es) 2014-03-20
NI201300127A (es) 2014-02-25
KR102066755B1 (ko) 2020-01-15
TWI624271B (zh) 2018-05-21
MX361716B (es) 2018-12-14
EP2714004A1 (en) 2014-04-09
PH12013502550A1 (en) 2015-08-10
JP2014520090A (ja) 2014-08-21
CR20130653A (es) 2014-03-05
HRP20240781T1 (hr) 2024-09-13
EP2714004B1 (en) 2024-05-15
BR112013030104A8 (pt) 2021-09-08
EP4427814A2 (en) 2024-09-11
CL2013003365A1 (es) 2014-07-25
CA2836847C (en) 2021-06-29
US11433120B2 (en) 2022-09-06
AU2012260821B2 (en) 2016-01-07
BR112013030104A2 (pt) 2016-09-20
CN108283619B (zh) 2021-09-14
RS65702B1 (sr) 2024-07-31
AU2016202156B2 (en) 2018-03-22
ES2984717T3 (es) 2024-10-30
CN103702662B (zh) 2018-07-20
NZ617828A (en) 2016-11-25
LT2714004T (lt) 2024-08-12
CN108283619A (zh) 2018-07-17
EA201391675A1 (ru) 2014-08-29
US20210308226A1 (en) 2021-10-07
TW201249463A (en) 2012-12-16
IL229376B (en) 2019-11-28
KR20140045438A (ko) 2014-04-16
AU2016202156A1 (en) 2016-04-28
JP6415673B2 (ja) 2018-10-31
PT2714004T (pt) 2024-07-12
PH12013502550B1 (en) 2015-08-10
AR086577A1 (es) 2014-01-08
WO2012160213A1 (en) 2012-11-29
ECSP13013107A (es) 2015-03-31
CA2836847A1 (en) 2012-11-29
JP6265888B2 (ja) 2018-01-24

Similar Documents

Publication Publication Date Title
DOP2013000275A (es) Formulaciones peptídicas de liberación controlada
AR106049A1 (es) Formulaciones de liberación controlada
PE20141297A1 (es) Formulaciones peptidicas robustas de liberacion controlada
MX2020011166A (es) Agentes crioprotectores para formulaciones en forma de particulas.
MX2018015709A (es) Derivados de azabencimidazol como inhibidores de pi3k beta.
AR083016A1 (es) Formulaciones liquidas para la agricultura con una mejor estabilidad
CU24400B1 (es) Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas
MX2019003520A (es) Mezclas y formulacions que comprenden una sal de alquil amonio de acido etilendiaminotetraacetico (edta).
CU20200008A7 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen
PE20131359A1 (es) Composiciones que contienen un insecticida de piripiropeno y una base
GT201600060A (es) Formulaciones de espuma y aparatos para suminstro
MX345256B (es) Formulaciones estables para inyeccion parenteral de farmacos de molecula pequeña.
EA201791166A1 (ru) Препараты с контролируемым высвобождением
DOP2017000018A (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
MX2019002999A (es) Formulaciones de analogo de prostaciclina.
AR099097A1 (es) SUSPOEMULSIÓN ACUOSA QUE CONTIENE l-CIALOTRINA Y MÉTODOS PARA PRODUCIR Y USAR LA MISMA
BR112015002041A2 (pt) formulação transdérmica contendo inibidores de cox
TN2014000483A1 (en) Somatostatin receptor agonist formulations
MX375485B (es) Derivados biciclicos de piridina, pirazina y pirimidina como inhibidores de pi3k beta
MX2021007194A (es) Formulacion insecticida para el control de vectores y plagas con eficacia de contacto incrementada.
MX2019011610A (es) Derivados de quinoxalina y piridoprazina como inhibidores de pi3k-beta.
HK1239563A1 (en) Controlled-release formulations
CO2018000525A2 (es) Concentrado que contiene alprostadil